NCT04663204View on ClinicalTrials.gov

A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Immunoglobulin A NephropathyKidney DiseasesGlomerulonephritis, IGAGlomerulonephritisAutoimmune DiseasesImmune System Diseases
Interventions
DRUG

Sparsentan

Target dose of 400 mg daily

Trial Locations (5)

Unknown

Cambridge University Hospitals NHS Trust, Cambridge

Northern Care Alliance NHS Foundation Trust - Salford Royal, Salford

Royal Infirmary of Edinburgh & Western General Hospital, Edinburgh

CF14 4XW

University Hospital of wales, Cardiff

LE5 4PW

Leicester General Hospital, University Hospitals of Leicester NHS Trust, Leicester

All Listed Sponsors
collaborator

Travere Therapeutics, Inc.

INDUSTRY

lead

University of Leicester

OTHER